Kennedy asserted that a thorough review of scientific literature led to this funding shift, claiming that the existing mRNA vaccines "fail to protect effectively" against illnesses such as Covid and flu. He advocated for a transition toward "safer, broader vaccine platforms" capable of adapting to viral mutations. However, experts contend that viruses naturally mutate regardless of vaccination status, and that mRNA vaccines possess a strong safety record.
Peter Lurie, a former FDA official, emphasized the importance of mRNA technology in pandemic response, stressing that this funding cut could impede future protective measures. Moreover, while Kennedy's moves signal a significant policy shift within the HHS—such as his recent dismissal of committee members who support traditional immunization guidelines—health professionals warn of the potentially detrimental impacts of these choices. The HHS plans to prioritize vaccine development with a focus on safety and transparency as mRNA technology's future hangs in the balance.
Peter Lurie, a former FDA official, emphasized the importance of mRNA technology in pandemic response, stressing that this funding cut could impede future protective measures. Moreover, while Kennedy's moves signal a significant policy shift within the HHS—such as his recent dismissal of committee members who support traditional immunization guidelines—health professionals warn of the potentially detrimental impacts of these choices. The HHS plans to prioritize vaccine development with a focus on safety and transparency as mRNA technology's future hangs in the balance.